Effects of food on the pharmacokinetics of irbesartan/hydrochlorothiazide combination tablet

Clinical Drug Investigation

Volumn 16, Issue 5, 1998, Pages 399-404

  Vachharajani, N N ^a   Shyu, W C ^a   Greene, D S ^a   Uderman, H D ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG MIXTURE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031789783     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816050-00008     Document Type: Article

References (24)

1. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II antagonists. Pharmacol Rev 1993; 45: 205-51
2. Eberhardt RT, Kevak RM, Kang PM, et al. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993; 33: 1023-38
3. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826-34
4. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9
5. Ribstein J, Sissman J, Picard A, et al. Effect on the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 1994; 12 Suppl. 3: 131
6. Necciari J, Denolle T, Le Croz F, et al. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man. J Hypertens 1994; 12 Suppl. 3: 88
7. Marino MR, Langenbacher KM, Ford NF, et al. Safety, tolerabiltty, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects. Clin Pharmacol Ther 1997; 61: 207
8. Kaplan NM. Implications for cost-effectiveness. Combination therapy for systemic hypertension. Am J Cardiol 1995; 76: 595-7
9. Pool JL, Guthrie RM, Littlejohn TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-70
10. Rosenstock J, Rossi L, Lin CS, et al. The efficacy and safety of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients nonresponsive to hydrochlorothiazide alone [abstract]. J Hypertens 1997; 15 Suppl. 4: S189
11. Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm 1977; 5: 291-334
12. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978; 3: 337-51
13. Chang S-Y, Whigan DB, Vachharajani NN, et al. A high-performance liquid chromatography assay for quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine. J Chromatogr B Biomed Appl 1997; 702: 149-55
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc., 1982: 409-17
15. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980; 8: 509-34
16. Barbhaiya RH, Craig WA, Corrick-West HP, et al. Pharmacokinetics of hydrochlorothiazide in fasted and fed subjects: a comparison of plasma and urinary excretion methods. J Pharm Sci 1982; 71: 245-8
17. Welling PG, Barbhaiya RH. Influence of food and fluid volume on chlorthiazide bioavailability: comparison of plasma and urine excretion methods. J Pharm Sci 1982; 71: 32-5
18. Vessel ES. Complex effects of diet on drug disposition. Clin Pharmacol Ther 1984; 36: 285-96
19. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs 1976; 11: 45-54
20. Welling PG, Koch PA, Lau CC, et al. Unavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977; 11: 462-9
21. Shyu WC, Knupp CA, Pittman KA, et al. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991; 50: 503-7
22. Melander A, Danielson K, Schersten B, et al. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 1977; 22: 108-12
23. Levy RH, Pitlick WH, Troupin AS, et al. Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 1975; 17: 657-68
24. Vachharajani NN, Shyu WC, Mantha S, et al. Lack of effect of food on the oral bioavailability of irbesartan in healthy volunteers. J Clin Pharmacol 1998; 38: 433-6